COVID-19 Stops Non-Essential Pharma-Bio Capex Projects in California, Pennsylvania, an Industrial Info Market Brief
COVID-19 Stops Non-Essential Pharma-Bio Capex Projects in California, Pennsylvania, an Industrial Info Market Brief
While the Pharma-Bio Industry is classified as an essential industry in the era of COVID-19, it is becoming apparent that a number of big-ticket projects are being shut down. California and Pennsylvania were the first two states to issue stay-in-place orders, and it soon became clear that non-essential large capex projects had ground to a halt.
In California, Bayer shut down its $150 million cell culture tech center in Berkeley, as did Cytokinetics and its $200 million project in South San Francisco.
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- Pennsylvania Sees $9.3 Billion in Projects Under Construction
- Bayer Seeks to Expand Global Agro Footprint with Proposed Monsanto Acquisit...
- West Coast Surfs into Second-Quarter 2015 on $1 Billion Wave of Life-Scienc...
- Pharma-Biotech Industry Capital Investment Tops $12 Billion for North Ameri...
- New England Sees $27 Billion in Projects Under Construction